From the Competence Centre for Thyroid Diseases-Clinic for Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale.
Clin Nucl Med. 2022 Mar 1;47(3):253-254. doi: 10.1097/RLU.0000000000003946.
In recent years, a large number of articles have described the endocrine-related adverse events associated with immune checkpoint inhibitors, especially affecting the thyroid. A 37-year-old man affected by nasopharyngeal carcinoma (stage IVb) underwent serial 18F-FDG PET/CT evaluations during treatment with nivolumab (480 mg every 4 weeks) after first-line chemoradiotherapy. The patient had no history of thyroid disease and before starting immunotherapy the thyroid-stimulating hormone value was normal at 0.9 mU/L (reference range, 0.27-4.2 mIU/L). FDG PET/CT studies revealed involution of the thyroid gland following immune checkpoint inhibitor-induced thyroiditis.
近年来，大量文章描述了与免疫检查点抑制剂相关的内分泌相关不良事件，特别是影响甲状腺。一名 37 岁的男性患有鼻咽癌（IVb 期），在一线放化疗后接受纳武利尤单抗（每 4 周 480mg）治疗期间，进行了多次 18F-FDG PET/CT 评估。该患者无甲状腺疾病史，在开始免疫治疗前，促甲状腺激素值正常，为 0.9mU/L（参考范围，0.27-4.2mIU/L）。FDG PET/CT 研究显示，在免疫检查点抑制剂诱导的甲状腺炎后，甲状腺发生退行性变。
